Immune responses to adeno-associated virus and its recombinant vectors

被引:0
|
作者
J Y Sun
V Anand-Jawa
S Chatterjee
K K Wong
机构
[1] Division of Hematology and Stem Cell Transplantation,Division of Virology
[2] City of Hope,undefined
来源
Gene Therapy | 2003年 / 10卷
关键词
recombinant adeno-associated virus (rAAV) vectors; immunogenicity; genetic vaccination;
D O I
暂无
中图分类号
学科分类号
摘要
Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV-encoded transgenes, raising the potential for their use in vaccine development. In this review, we summarize current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
引用
收藏
页码:964 / 976
页数:12
相关论文
共 50 条
  • [21] Innate Immune Sensing of Adeno-Associated Virus Vectors
    Cao, Di
    Byrne, Barry J.
    de Jong, Ype P.
    Terhorst, Cox
    Duan, Dongsheng
    Herzog, Roland W.
    Kumar, Sandeep R. P.
    HUMAN GENE THERAPY, 2024, 35 (13-14) : 451 - 463
  • [22] Integration of adeno-associated virus (AAV) and recombinant AAV vectors
    McCarty, DM
    Young, SM
    Samulski, RJ
    ANNUAL REVIEW OF GENETICS, 2004, 38 : 819 - 845
  • [23] Development and targeting of recombinant adeno-associated virus (rAAV) vectors
    Hallek, M
    Girod, A
    Büning, H
    Ried, M
    Leike, K
    Hutter, M
    Huttner, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S33 - S33
  • [24] Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
    Li, Leyao
    Vasan, Lakshmy
    Kartono, Bryan
    Clifford, Kevan
    Attarpour, Ahmadreza
    Sharma, Raghav
    Mandrozos, Matthew
    Kim, Ain
    Zhao, Wenda
    Belotserkovsky, Ari
    Verkuyl, Claire
    Schmitt-Ulms, Gerold
    BIOMEDICINES, 2023, 11 (10)
  • [25] Recombinant adeno-associated virus vectors in the treatment of rare diseases
    Hastie, Eric
    Samulski, R. Jude
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (06): : 675 - 689
  • [26] A simplified purification protocol for recombinant adeno-associated virus vectors
    Potter, Mark
    Lins, Bridget
    Mietzsch, Mario
    Heilbronn, Regine
    Van Vliet, Kim
    Chipman, Paul
    Agbandje-McKenna, Mavis
    Cleaver, Brian D.
    Clement, Nathalie
    Byrne, Barry J.
    Zolotukhin, Sergei
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2014, 1 : 14034
  • [27] Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors
    Basner-Tschakarjan, Etiena
    Bijjiga, Enoch
    Martino, Ashley T.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [28] Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo
    Gao, GP
    Qu, G
    Burnham, MS
    Huang, J
    Chirmule, N
    Joshi, B
    Yu, QC
    Marsh, JA
    Conceicao, CM
    Wilson, JM
    HUMAN GENE THERAPY, 2000, 11 (15) : 2079 - 2091
  • [29] Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
    Bartlett, JS
    Wilcher, R
    Samulski, RJ
    JOURNAL OF VIROLOGY, 2000, 74 (06) : 2777 - 2785
  • [30] Adeno-associated virus and the development of adeno-associated virus vectors: A historical perspective
    Carter, BJ
    MOLECULAR THERAPY, 2004, 10 (06) : 981 - 989